ScinoPharm To Supply Antidepressant API

ScinoPharm has been selected by Clinical Data, Inc. to provide the manufacture of vilazodone hydrochloride API for Viibryd, a recently FDA-approved antidepressant. Viibryd is for the treatment of adults with major depressive disorder (MDD). The drug is different from other antidepressants in that it does not cause significant weight gain or interference with sexual function.

“ScinoPharm is proud of the fruitful partnership with Clinical Data by being its sole API supplier of vilazodone hydrochloride during Viibryd’s launch. Beginning from process research through timely development and optimization of long and complicated synthetic processes, we have established a win-win partnership,” said Dr. Jo Shen, president and chief executive officer of ScinoPharm.